Reported Sunday, Viking Therapeutics Reports 74% Of Subcutaneous VK2735 Participants Improved BMI Category Versus 15% On Placebo After 13 Weeks, With Improved Cardiometabolic Markers
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
Viking Therapeutics (VKTX) Heads To Two Conferences, Is The Discount To Analyst Targets Warranted?
Is Viking Therapeutics (VKTX) Priced For Perfection After ObesityWeek?
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
Viking Therapeutics to Participate at Upcoming Investor Conferences
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
Viking Therapeutics: A Strong Injection, A Scaled-Back Pill
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)
VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress
Viking Therapeutics, Inc. Q3 2026 Earnings Call Summary
Viking Therapeutics Stock Jumps: What's Going On?
Viking Therapeutics (VKTX) Posted Wider Losses, Is The Stock Overvalued?
Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stock
Viking Therapeutics Q3 Earnings Call Highlights
Viking (VKTX) Q3 2026 Earnings Call Transcript
VKTX Stock Slides Overnight After Q3 Loss: CEO’s Obesity Drug Launch Timeline Frustrates Retail
Viking Therapeutics (NASDAQ:VKTX) Q3 2026 Earnings: Wider Loss as Obesity Pipeline Advances
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.